Angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
== Structure == Six tau isoforms exist in human brain tissue, and they are distinguished by their number of binding domains. Three isoforms have three binding domains and the other three have four binding domains. The binding domains are located in the carboxy-terminus of the protein and are positively charged (allowing it to bind to the negatively charged microtubule). The isoforms with four binding domains are better at stabilizing microtubules than those with three binding domains. Tau is a phosphoprotein with 79 potential serine (Ser) and threonine (Thr) phosphorylation sites on the longest tau isoform. Phosphorylation has been reported on approximately 30 of these sites in normal tau proteins. Phosphorylation of tau is regulated by a host of kinases, including PKN, a serine/threonine kinase. When PKN is activated, it phosphorylates tau, resulting in disruption of microtubule organization. Phosphorylation of tau is also developmentally regulated. For example, fetal tau is more highly phosphorylated in the embryonic CNS than adult tau. The degree of phosphorylation in all six isoforms decreases with age due to the activation of phosphatases. Like kinases, phosphatases too play a role in regulating the phosphorylation of tau. For example, PP2A and PP2B are both present in human brain tissue and have the ability to dephosphorylate Ser396. The binding of these phosphatases to tau affects tau's association with microtubules. Phosphorylation of tau has also been suggested to be regulated by O-GlcNAc modification at various Ser and Thr residues.
De Duve won the Francqui Prize for Biological and Medical Sciences in 1960, and the Nobel Prize for Physiology or Medicine in 1974. King Baudouin of Belgium honoured him to Viscount in 1989. He was the recipient of the Gairdner Foundation International Award in 1967, and the Dr H.P. Heineken Prize for Biochemistry and Biophysics in 1973 from the Royal Netherlands Academy of Arts and Sciences. He was elected a foreign associate of the National Academy of Sciences (United States) in 1975. He won the Harden Medal of the Biochemical Society of Great Britain in 1978; the Theobald Smith Award from the Albany Medical College in 1981; the Jimenez Diaz Award in 1985; the Innovators of Biochemistry Award from Medical College of Virginia in 1986; and the E.B. Wilson Medal in 1989. He was also a member of the Royal Academies of Medicine and the Royal Academy of Sciences, Arts, and of Literature of Belgium; the Pontifical Academy of Sciences of the Vatican; the American Academy of Arts and Sciences; the French National Academy of Medicine; the Academy of Sciences of Paris; the Deutsche Akademie der Naturforscher Leopoldina; the American Philosophical Society. He was elected a Foreign Member of the Royal Society (ForMemRS) in 1988. In addition, he received honorary doctorates from eighteen universities around the world.
EC 1.1.99.9: pyridoxine 5-dehydrogenase EC 1.1.99.10: Now EC 1.1.5.9, glucose 1-dehydrogenase (FAD, quinone) EC 1.1.99.11: Now classified as EC 1.1.5.14, fructose 5-dehydrogenase EC 1.1.99.12: sorbose dehydrogenase EC 1.1.99.13: glucoside 3-dehydrogenase EC 1.1.99.14: glycolate dehydrogenase EC 1.1.99.15: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.99.16: Now EC EC 1.1.5.4, malate dehydrogenase (quinone) EC 1.1.99.17: Now EC 1.1.5.2, quinoprotein glucose dehydrogenase EC 1.1.99.18: cellobiose dehydrogenase (acceptor) EC 1.1.99.19: Now EC 1.17.99.4, uracil/thymine dehydrogenase EC 1.1.99.20: alkan-1-ol dehydrogenase (acceptor) EC 1.1.99.21: D-sorbitol dehydrogenase (acceptor) EC 1.1.99.22: glycerol dehydrogenase (acceptor) EC 1.1.99.23: Now EC 1.1.2.6, polyvinyl alcohol dehydrogenase (cytochrome) EC 1.1.99.24: hydroxyacid-oxoacid transhydrogenase EC 1.1.99.25: Now EC 1.1.5.8, quinate dehydrogenase (quinone), EC 1.1.99.26: 3-hydroxycyclohexanone dehydrogenase EC 1.1.99.27: (R)-pantolactone dehydrogenase (flavin) EC 1.1.99.28: glucose-fructose oxidoreductase EC 1.1.99.29: pyranose dehydrogenase (acceptor) EC 1.1.99.30: 2-oxoacid reductase EC 1.1.99.31: (S)-mandelate dehydrogenase EC 1.1.99.32: L-sorbose 1-dehydrogenase EC 1.1.99.33: Now EC 1.17.99.7, formate dehydrogenase (acceptor) EC 1.1.99.34: now EC 1.1.98.2, glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.99.35: soluble quinoprotein glucose dehydrogenase EC 1.1.99.36: alcohol dehydrogenase (nicotinoprotein) EC 1.1.99.37: methanol dehydrogenase (nicotinoprotein) EC 1.1.99.38: 2-deoxy-scyllo-inosamine dehydrogenase (AdoMet-dependent) EC 1.1.99.39: D-2-hydroxyglutarate dehydrogenase EC 1.1.99.40: (R)-2-hydroxyglutarate—pyruvate transhydrogenase EC 1.1.99.41: 3-hydroxy-1,2-didehydro-2,3-dihydrotabersonine reductase EC 1.1.99.42: 4-pyridoxic acid dehydrogenase
=== Other treatments === Bracing can be used for unstable joints, though it has weak evidence as a pain management strategy. Neuromuscular taping can help prevent injury. TENS units are sometimes used for pain relief. Heat and cold treatment can also help to relieve pain, and have no adverse effects.
Sources: en.wikipedia.org
In 1896, Theodor Herzl, a Jewish journalist living in Austria-Hungary, published the foundational text of political Zionism, Der Judenstaat ("The Jews' State" or "The State of the Jews"), in which he asserted that the only solution to the "Jewish Question" in Europe, including growing anti-Semitism, was the establishment of a state for the Jews. A year later, Herzl founded the Zionist Organization, which at its first congress called for the establishment of "a home for the Jewish people in Palestine secured under public law". Proposed measures to attain that goal included the promotion of Jewish settlement there, the organisation of Jews in the diaspora, the strengthening of Jewish feeling and consciousness, and preparatory steps to attain necessary governmental grants. Herzl died in 1904, 44 years before the establishment of State of Israel, the Jewish state that he proposed, without having gained the political standing required to carry out his agenda. Zionist leader Chaim Weizmann, later President of the World Zionist Organisation and first President of Israel, moved from Switzerland to the UK in 1904 and met Arthur Balfour – who had just launched his 1905–1906 election campaign after resigning as Prime Minister – in a session arranged by Charles Dreyfus, his Jewish constituency representative. Earlier that year, Balfour had successfully driven the Aliens Act through Parliament with impassioned speeches regarding the need to restrict the wave of immigration into Britain from Jews fleeing the Russian Empire.
The classification according to the Four Natures (四气; sì qì): hot, warm, cool, or cold (or, neutral in terms of temperature) and hot and warm herbs are used to treat cold diseases, while cool and cold herbs are used to treat heat diseases. The classification according to the Five Flavors, (五味; wǔ wèi, sometimes also translated as Five Tastes): acrid, sweet, bitter, sour, and salty. Substances may also have more than one flavor, or none (i.e., a "bland" flavor). Each of the Five Flavors corresponds to one of zàng organs, which in turn corresponds to one of the Five Phases. A flavor implies certain properties and therapeutic actions of a substance; e.g., saltiness drains downward and softens hard masses, while sweetness is supplementing, harmonizing, and moistening. The classification according to the meridian – more precisely, the zàng-fu organ including its associated meridian – which can be expected to be primarily affected by a given compound.
=== Viral-mediated delivery === The gene silencing effects of transfected, designed siRNA are generally transient, but this difficulty can be overcome through an RNAi approach. Delivering this siRNA from DNA templates can be done through several recombinant viral vectors based on retrovirus, adeno-associated virus, adenovirus, and lentivirus. As of primary research work in 2006, the latter virus was the most efficient for stable delivery of siRNA to target cells, as it could be used to transduce nondividing cells, as well as to directly target the nucleus. These specific viral vectors have been synthesized to effectively facilitate siRNA that is not viable for transfection into cells. In some cases synthetic viral vectors can integrate siRNA into the cell genome, which allows for stable expression of siRNA and long-term gene knockdown. This technique is advantageous because it is an in vivo method, and can be effective for difficult to transfect cells. However, problems arise because it can trigger antiviral responses in some cell types, leading to mutagenic and immunogenic effects. This method has been shown to have potential for use in gene silencing of the central nervous system genes, e.g., in the treatment of Huntington's disease.
Liposarcoma treatment usually consists of surgical resection, with chemotherapy considered depending on the aggressiveness of the sarcoma. Radiotherapy may also be used before or after surgical excision for liposarcoma. Pediatric rhabdomyosarcoma is usually treated with chemotherapy, surgery, and sometimes radiotherapy. Pediatric rhabdomyosarcoma patients have a 50–85% long term survival rate. Osteosarcoma is a cancer of the bone that is treated with surgical resection of as much of the cancer as possible, often along with chemotherapy. Radiotherapy is a second alternative to surgery, although not as successful. It was believed that higher doses of chemotherapy might improve survival. However, high doses of chemotherapy stop the production of blood cells in the bone marrow and can be harmful. Stem cells collected from people before high‐dose chemotherapy can be transplanted back to the person if the blood cell count gets too low; this is called autologous hematopoietic stem cell transplantation, or high dose therapy with stem cell rescue. Research to investigate if using high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation was more favourable than standard‐dose chemotherapy found only one RCT and this did not favour either of the two treatment arms with respect to overall survival. As a result, high dose chemotherapy with stem cell rescue is generally considered appropriate only in the research setting.
Stress granule assembly is dependent upon the conditions of the cell. In yeast, stress granules form under conditions of high heat. Stress granules are of significance for their roles in mRNA localization, cell signaling pathways, and antiviral processes. Once disassembled, the RNA inside stress granules can go back to translation or be removed as cellular waste. Stress granules may provide protection for mRNA from interactions with the cytosol. Moreover, mutations that affect the formation or degradation of stress granules may contribute to neurodegenerative conditions such as ALS and FTLD. However, the effects of stress granules on cell physiology are still under study.
Sources: en.wikipedia.org
==== Eye care ==== Moisture replacement therapies such as artificial tears may ease the symptoms of dry eyes. Some patients with more severe problems use goggles to increase local humidity or have punctal plugs inserted to help retain tears on the ocular surface for a longer time. Additionally, chronic dry eyes can be treated with prescription eyedrops that suppress the inflammation that disrupts tear secretion, such as cyclosporine (Restasis®, Cequa®, Vevye®) and lifitegrast (Xiidra®); or eyedrops that prevent tear evaporation, such as perfluorohexyloctane (Miebo®). Prescription drugs are also available that help to stimulate salivary flow, such as cevimeline (Evoxac) and pilocarpine. Salagen, a manufactured form of pilocarpine, can be used to help produce tears, as well as saliva in the mouth and intestines. It is derived from the jaborandi plant.
=== Development === In younger people the plantar fascia is also intimately related to the Achilles tendon, with a continuous fascial connection between the two from the distal aspect of the Achilles to the origin of the plantar fascia at the calcaneal tubercle. However, the continuity of this connection decreases with age to a point that in the elderly there are few, if any, connecting fibers. There are also distinct attachments of the plantar fascia and the Achilles tendon to the calcaneus so the two do not directly contact each other. Nevertheless, there is an indirect relationship whereby if the toes are dorsiflexed, the plantar fascia tightens via the windlass mechanism. If a tensile force is then generated in the Achilles tendon it will increase tensile strain in the plantar fascia. Clinically, this relationship has been used as a basis for treatment for plantar fasciitis, with stretches and night stretch splinting being applied to the gastrocnemius/soleus muscle unit.
=== Anime === An anime television series adaptation of the first part was announced on April 10, 2025. It is produced by Wit Studio and directed by Ken Yamamoto, with Kazuhiro Furuhashi serving as animation adviser, Ayumu Hisao handling series composition, Namiko Torii designing the characters, and Kensuke Ushio composing the music. The series aired from March 29 to June 28, 2026 on Tokyo MX and other networks, with an advance screening held on March 15 of the same year at Shinjuku Wald 9 in Tokyo. The opening theme song is "Petals" (ペタルズ, Petaruzu), while the ending theme song is "Hana Ikada" (花筏), both performed by Orangestar featuring Kase. Crunchyroll is streaming the series in simulcast with an English dub. Muse Communication licensed the series in Southeast Asia.
Cytochrome-b5 reductase is a NADH-dependent enzyme that converts ferricytochrome from a Fe3+ form to a Fe2+ form. It contains FAD and catalyzes the reaction: In its b5-reducing capacity, this enzyme is involved in desaturation and elongation of fatty acids, cholesterol biosynthesis, and drug metabolism. This enzyme can also reduce methemoglobin to normal hemoglobin, gaining it the inaccurate synonym methemoglobin reductase. Isoforms expressed in erythrocytes (CYB5R1, CYB5R3) perform this function in vivo. Ferricyanide is another substrate in vitro.
British endocrinologist Albert T. W. Simeons proposed HCG as an adjunct to an ultra-low-calorie weight-loss diet (fewer than 500 calories). Simeons, while studying pregnant women in India on a calorie-deficient diet, and obese boys with pituitary issues (Frölich's syndrome) treated with low-dose HCG, observed that both lost fat rather than lean (muscle) tissue. He reasoned that HCG must be programming the hypothalamus to do this in the former cases in order to protect the developing fetus by promoting mobilization and consumption of abnormal, excessive adipose deposits. Simeons in 1954 published a book entitled Pounds and Inches, designed to combat obesity. Simeons, practicing at Salvator Mundi International Hospital in Rome, Italy, recommended low-dose daily HCG injections (125 IU) in combination with a customized ultra-low-calorie (500 cal/day, high-protein, low-carbohydrate/fat) diet, which was supposed to result in a loss of adipose tissue without loss of lean tissue. Other researchers did not find the same results when attempting experiments to confirm Simeons' conclusions, and in 1976 in response to complaints the FDA required Simeons and others to include the following disclaimer on all advertisements:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.